International Clinical Trials Day 2019
20 May 2019
Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.
We want to take today to say a special thank you to our wonderful Clinical Trials team, and extend our appreciation to the many thousands of dedicated people that undertake clinical trials to advance medicine and treatments for patients. Today is also an opportunity to recognise patients and their contribution to finding a cure by choosing to participate in our trials.
Our 20-person team based at the Poche Centre is currently coordinating 18 actively recruiting trials, while maintaining follow-up for a further 23. The trials coordinated by the team range from surgical and dermatological trials, through the spectrum of available medical and radiation oncology trials, including immunotherapy, targeted therapy, and radiation therapy. In 2018, 244 new patients were enrolled in clinical trials at MIA, while 665 were in the follow-up stages.
“We are very fortunate here at MIA to have an extremely hardworking and inspiring Clinical Trials team who are one hundred percent dedicated to our patients,” says Co-Medical Director Professor Richard Scolyer.
Co-Medical Director Professor Georgina Long adds, “Clinical trials lead to advances in treatment that create better outcomes for our patients – continually pushing the boundaries and conducting these trials is what is going to help us achieve our goal of zero deaths of melanoma.”
International Clinical Trials Day commemorates the day Scottish doctor James Lind began the first ever clinical trial in 1747, using different groups of sailors to identify the link between fruit and the prevention of scurvy. Lind changed modern medicine with his study, so every year International Clinical Trials Day is celebrated to appreciate and highlight the work of those in Clinical Trials.
Clinical Trials Manager Maria Gonzalez echoed the sentiments of the whole team, “We all come to work each day for the same reason: to help patients and find a cure.”
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.